Shire: Unsupported Efficacy Claims to Prescribers and Medicaid Committees

In the Shire pharmaceutical fraud settlement, Shire agreed to pay $56.5 million to resolve allegations of misleading promotion involving five drugs. The alleged sales effort reached doctors, state Medicaid formulary committees and the staff handling requests for prescription coverage.

For someone inside drug development, medical affairs or sales, the case turns on a recognizable gap: what the evidence showed, what the company said, and what it told the people deciding whether public money would pay for the prescription.

The Department of Justice announced the civil settlement on September 24, 2014. Shire, based in Wayne, Pennsylvania, manufactured and sold Adderall XR, Vyvanse and Daytrana for attention deficit hyperactivity disorder, and Lialda and Pentasa for mild to moderate active ulcerative colitis. The pharmaceutical fraud case grew out of separate whistleblower lawsuits brought by a former executive and former sales representatives.

Adderall XR and the Promise to Normalize Children

The government alleged that Shire overstated Adderall XR’s effectiveness from January 2004 through December 2007, including claims that it was clinically superior to competing ADHD drugs. The pitch was that it could make children with ADHD indistinguishable from their peers without the condition, and that competing products could not do the same.

That is a powerful promise to put in front of a parent or prescriber. The government said Shire’s clinical data did not support the comparison.

The whistleblower’s complaint went further into how the claim was built. It said the study behind the pitch never measured what the pitch claimed:

The alleged comparison came from an analysis performed after the study, rather than a study designed to answer the question the promotion posed. A sales aid can cite a real study and still ask it to prove something it never measured.

The Justice Department also alleged that Shire promoted Adderall XR as preventing poor academic performance, job loss, traffic accidents and sexually transmitted disease without supporting evidence. The alleged pitch turned an ADHD medicine into protection against life going wrong. Separately, the government alleged that Shire promoted the drug for conduct disorder without Food and Drug Administration approval.

Vyvanse Claims Reached the Medicaid Formulary Committee

Shire allegedly made false and misleading statements about Vyvanse’s effectiveness and potential for abuse to state Medicaid formulary committees and individual physicians from February 2007 through September 2010. The government’s account of the committee presentation describes a medical science liaison claiming that Vyvanse carried less risk of abuse than every other long-acting release mechanism on the market.

The government said no Shire study had concluded that Vyvanse could not be abused. The amphetamine product also carried a boxed warning required by the Food and Drug Administration about misuse and abuse. The whistleblower’s amended complaint alleged that sales representatives and medical science liaisons promoted Vyvanse as non-abuseable even though the study offered in support concluded that it remained subject to abuse.

The committee audience matters. Formularies help determine which drugs a program covers and under what conditions. Prior authorization can require approval for an individual prescription. A physician chooses treatment for a patient, while a formulary decision can shape access across the program. An unsupported claim about safety or comparative effectiveness therefore has a commercial use well beyond the examining room.

In Shire’s case, the alleged pitch reached both places. The government described a medical science liaison addressing a Medicaid board and sales staff making claims to physicians. The government also alleged unsupported claims that Vyvanse would prevent car accidents, divorce, arrests and unemployment. The product’s alleged selling points reached from the patient’s future to the public program’s coverage decision.

When Sales Staff Entered the Prior-Authorization Process

The government alleged that Shire representatives made calls and drafted letters to state Medicaid authorities to help physicians obtain prior authorization for Daytrana and Vyvanse. It said the purpose was to induce physicians to prescribe those drugs.

This is where the case moves from a promotional statement into the paperwork used to obtain coverage. The complaint described authorization requests containing patient and provider identifiers and clinical information about the requested treatment. Those details give the request its apparent medical authority.

The amended complaint alleged that some sales representatives went beyond helping a physician’s office:

The complaint said Shire’s compliance department investigated and initially thought the conduct involved only two representatives, then found it more widespread. It separately alleged that numerous representatives completed and submitted authorization forms for Adderall XR and Vyvanse.

The identity behind the request is part of the manufacturer-run prior authorization issue. In this allegation, Medicaid could receive what appeared to be a request from a qualified professional or office employee when a drug salesperson had prepared and submitted it. The same company seeking the prescription was allegedly supplying the voice asking the public program to cover it.

Daytrana’s Patch and the Gastrointestinal Drugs

The Daytrana allegations concerned the patch’s promotion as less susceptible to abuse than traditional pills from April 2006 through September 2010. The delivery method was part of the alleged sales claim. The government’s account paired that message with the authorization assistance for Daytrana and Vyvanse.

The amended complaint also carried a separate allegation about what Shire knew of the patch itself. It said clinical-trial sites reported difficulties using the patch and that Shire advised site coordinators to refrigerate it. The whistleblower alleged that neither the difficulties nor those instructions were shared with the FDA in the drug’s approval application.

What Is Considered Off-Label Promotion?

Off-label promotion means promoting a drug for a use the Food and Drug Administration has not approved. The Shire settlement included allegations that sales representatives promoted Lialda and Pentasa for unapproved uses that federal healthcare programs did not cover, between January 2006 and June 2010.

Both drugs were approved for mild to moderate active ulcerative colitis. The government specifically alleged that Shire promoted Lialda to prevent colorectal cancer. The alleged pitch offered an additional use for the medicine, beyond the disease it was approved to treat.

The connection between off-label promotion and government payment runs through the use being promoted, the resulting prescription and the claim for coverage. Here, the government expressly identified the gastrointestinal uses as outside federal program coverage. That connects the promotional message to the taxpayers’ bill.

What the Executive and Sales Representatives Could See

The Shire case shows how pharmaceutical whistleblowers in different roles can expose different parts of a promotion campaign. The Justice Department identified a former executive behind one lawsuit and three former sales representatives behind another.

The executive’s original complaint described responsibility for research and development, global development and medical plans, drug-safety monitoring and interaction with regulators. That position offered a view of the studies and safety information behind the company’s messages. The sales role offered a view of how those messages reached prescribers and how the company helped secure coverage.

We look at those accounts together. A clinical employee may recognize that a comparison exceeds what a study measured. A sales employee may recognize the same comparison in a sales aid or know who completed an authorization request. The useful connection is between the scientific information, the message delivered and the prescription the program was asked to fund.

What the Settlement Required Shire to Pay and Change

The settlement allocated $35,713,965 to the federal government and $20,786,034 to state Medicaid programs.

The Florida Attorney General’s summary, published by the Department of Health and Human Services’ inspector general, identified $48.1 million as the Medicaid portion of the national settlement. It also described this as the first national settlement to calculate and include Medicaid managed-care damages.

Shire separately entered a corporate integrity agreement with the Department of Health and Human Services’ inspector general addressing future marketing. The Justice Department described comprehensive safeguards, oversight of promotional activities, and compliance certifications from the board and management.

How Much Money Do Pharmaceutical Whistleblowers Get for Exposing Fraud?

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. In the Shire settlement, the Justice Department announced a $5.9 million award for the former executive who brought the case.

Shire’s Later Dermagraft and Texas Settlements

Shire’s later settlements concerned different products or sales practices. In January 2017, the Justice Department announced a separate $350 million settlement over Dermagraft, a bioengineered skin substitute approved for diabetic foot ulcers. The government alleged that Shire and Advanced BioHealing, which Shire had acquired, used kickbacks and other unlawful methods to induce clinics and physicians to use or overuse it.

In August 2023, the Texas Attorney General announced a $42.7 million settlement involving Shire and other drug manufacturers. The allegations concerned nursing and reimbursement services provided to Texas Medicaid providers, as well as payments to clinical nurse educators to refer or recommend Vyvanse. That case focused on services and paid recommendations; the earlier promotion case focused on what Shire allegedly told prescribers and public payers about its drugs.

The promotion case makes the path from sales claim to payment unusually concrete. Shire’s alleged campaign put clinical comparisons before prescribers, abuse-risk claims before Medicaid committees and company representatives inside the authorization process. For an insider, the revealing discrepancy may be between a study and a sales aid, or between the person named on a request and the person who actually submitted it. Those are the connections our whistleblower experts examine with you.

You Know What the Study Actually Said

If you saw a drug claim change between the clinical evidence, the sales presentation and the Medicaid request, speak to one of our whistleblower experts about what you saw. We work with you to build your strongest pharmaceutical whistleblower case and bring in pharmaceutical promotion whistleblower lawyers who understand clinical claims and reimbursement. We stay beside you as the case develops, keeping your knowledge of the product and the company’s decisions at its center.